{"result": {"id": "5c9f8879-5113-456a-8e5c-698e1f1d631f", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>COMMITTEE OF CARDIO-CEREBRO-VASCULAR DISEASES OF GERONTOLOGICAL SOCIETY OF CHINA<|>ORGANIZATION<|>An organization involved in creating expert consensus on the use of Xuezhikang\")  \n##  \n(\"entity\"<|>WORKING GROUP OF CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>ORGANIZATION<|>A working group that contributed to the Chinese expert consensus on Xuezhikang\")  \n##  \n(\"entity\"<|>XUEZHIKANG<|>ORGANIZATION<|>A medical product discussed in the Chinese expert consensus\")  \n##  \n(\"entity\"<|>JIA W<|>PERSON<|>Researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>LI Y<|>PERSON<|>Researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>WAN J<|>PERSON<|>Researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>DAI N<|>PERSON<|>Researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>ZHAO FF<|>PERSON<|>Researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>FANG M<|>PERSON<|>Researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>XU RX<|>PERSON<|>Researcher involved in a study on Hedan Tablet's effects on lipid profile\")  \n##  \n(\"entity\"<|>WU NQ<|>PERSON<|>Researcher involved in a study on Hedan Tablet's effects on lipid profile\")  \n##  \n(\"entity\"<|>LI S<|>PERSON<|>Researcher involved in a study on Hedan Tablet's effects on lipid profile\")  \n##  \n(\"entity\"<|>DAS PRADHAN A<|>PERSON<|>Researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>GLYNN RJ<|>PERSON<|>Researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>FRUCHART JC<|>PERSON<|>Researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>GORDON SM<|>PERSON<|>Researcher involved in a study on niacin monotherapy's effect on HDL\")  \n##  \n(\"entity\"<|>AMAR MJ<|>PERSON<|>Researcher involved in a study on niacin monotherapy's effect on HDL\")  \n##  \n(\"entity\"<|>JEIRAN K<|>PERSON<|>Researcher involved in a study on niacin monotherapy's effect on HDL\")  \n##  \n(\"entity\"<|>TADIC M<|>PERSON<|>Researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>SALA C<|>PERSON<|>Researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>GRASSI G<|>PERSON<|>Researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>BHATT DL<|>PERSON<|>Researcher involved in a study on cardiovascular risk reduction with icosapent ethyl\")  \n##  \n(\"entity\"<|>STEG PG<|>PERSON<|>Researcher involved in a study on cardiovascular risk reduction with icosapent ethyl\")  \n##  \n(\"entity\"<|>MILLER M<|>PERSON<|>Researcher involved in a study on cardiovascular risk reduction with icosapent ethyl\")  \n##  \n(\"entity\"<|>NICHOLLS SJ<|>PERSON<|>Researcher involved in the STRENGTH Randomized Clinical Trial\")  \n##  \n(\"entity\"<|>LINCOFF AM<|>PERSON<|>Researcher involved in the STRENGTH Randomized Clinical Trial\")  \n##  \n(\"entity\"<|>GARCIA M<|>PERSON<|>Researcher involved in the STRENGTH Randomized Clinical Trial\")  \n##  \n(\"entity\"<|>AVERNA M<|>PERSON<|>Researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>BANACH M<|>PERSON<|>Researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>BRUCKERT E<|>PERSON<|>Researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>GOLDBERG AC<|>PERSON<|>Researcher involved in a study on bempedoic acid vs placebo\")  \n##  \n(\"entity\"<|>LEITER LA<|>PERSON<|>Researcher involved in a study on bempedoic acid vs placebo\")  \n##  \n(\"entity\"<|>STROES E<|>PERSON<|>Researcher involved in a study on bempedoic acid vs placebo\")  \n##  \n(\"relationship\"<|>COMMITTEE OF CARDIO-CEREBRO-VASCULAR DISEASES OF GERONTOLOGICAL SOCIETY OF CHINA<|>WORKING GROUP OF CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>Both organizations collaborated on the Chinese expert consensus on Xuezhikang<|>7\")  \n##  \n(\"relationship\"<|>JIA W<|>LI Y<|>Co-authors of a study on Xuezhitong for hypertriglyceridemia<|>6\")  \n##  \n(\"relationship\"<|>JIA W<|>WAN J<|>Co-authors of a study on Xuezhitong for hypertriglyceridemia<|>6\")  \n##  \n(\"relationship\"<|>LI Y<|>WAN J<|>Co-authors of a study on Xuezhitong for hypertriglyceridemia<|>6\")  \n##  \n(\"relationship\"<|>DAI N<|>ZHAO FF<|>Co-authors of a systematic review on Gynostemma pentaphyllum<|>6\")  \n##  \n(\"relationship\"<|>DAI N<|>FANG M<|>Co-authors of a systematic review on Gynostemma pentaphyllum<|>6\")  \n##  \n(\"relationship\"<|>ZHAO FF<|>FANG M<|>Co-authors of a systematic review on Gynostemma pentaphyllum<|>6\")  \n##  \n(\"relationship\"<|>XU RX<|>WU NQ<|>Co-authors of a study on Hedan Tablet<|>6\")  \n##  \n(\"relationship\"<|>XU RX<|>LI S<|>Co-authors of a study on Hedan Tablet<|>6\")  \n##  \n(\"relationship\"<|>WU NQ<|>LI S<|>Co-authors of a study on Hedan Tablet<|>6\")  \n##  \n(\"relationship\"<|>DAS PRADHAN A<|>GLYNN RJ<|>Co-authors of a study on pemafibrate<|>6\")  \n##  \n(\"relationship\"<|>DAS PRADHAN A<|>FRUCHART JC<|>Co-authors of a study on pemafibrate<|>6\")  \n##  \n(\"relationship\"<|>GLYNN RJ<|>FRUCHART JC<|>Co-authors of a study on pemafibrate<|>6\")  \n##  \n(\"relationship\"<|>GORDON SM<|>AMAR MJ<|>Co-authors of a study on niacin monotherapy<|>6\")  \n##  \n(\"relationship\"<|>GORDON SM<|>JEIRAN K<|>Co-authors of a study on niacin monotherapy<|>6\")  \n##  \n(\"relationship\"<|>AMAR MJ<|>JEIRAN K<|>Co-authors of a study on niacin monotherapy<|>6\")  \n##  \n(\"relationship\"<|>TADIC M<|>SALA C<|>Co-authors of a study on omega-3 fatty acids<|>6\")  \n##  \n(\"relationship\"<|>TADIC M<|>GRASSI G<|>Co-authors of a study on omega-3 fatty acids<|>6\")  \n##  \n(\"relationship\"<|>SALA C<|>GRASSI G<|>Co-authors of a study on omega-3 fatty acids<|>6\")  \n##  \n(\"relationship\"<|>BHATT DL<|>STEG PG<|>Co-authors of a study on icosapent ethyl<|>6\")  \n##  \n(\"relationship\"<|>BHATT DL<|>MILLER M<|>Co-authors of a study on icosapent ethyl<|>6\")  \n##  \n(\"relationship\"<|>STEG PG<|>MILLER M<|>Co-authors of a study on icosapent ethyl<|>6\")  \n##  \n(\"relationship\"<|>NICHOLLS SJ<|>LINCOFF AM<|>Co-authors of the STRENGTH Randomized Clinical Trial<|>6\")  \n##  \n(\"relationship\"<|>NICHOLLS SJ<|>GARCIA M<|>Co-authors of the STRENGTH Randomized Clinical Trial<|>6\")  \n##  \n(\"relationship\"<|>LINCOFF AM<|>GARCIA M<|>Co-authors of the STRENGTH Randomized Clinical Trial<|>6\")  \n##  \n(\"relationship\"<|>AVERNA M<|>BANACH M<|>Co-authors of a European Atherosclerosis Society Task Force statement<|>6\")  \n##  \n(\"relationship\"<|>AVERNA M<|>BRUCKERT E<|>Co-authors of a European Atherosclerosis Society Task Force statement<|>6\")  \n##  \n(\"relationship\"<|>BANACH M<|>BRUCKERT E<|>Co-authors of a European Atherosclerosis Society Task Force statement<|>6\")  \n##  \n(\"relationship\"<|>GOLDBERG AC<|>LEITER LA<|>Co-authors of a study on bempedoic acid<|>6\")  \n##  \n(\"relationship\"<|>GOLDBERG AC<|>STROES E<|>Co-authors of a study on bempedoic acid<|>6\")  \n##  \n(\"relationship\"<|>LEITER LA<|>STROES E<|>Co-authors of a study on bempedoic acid<|>6\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166443, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2550, "prompt_tokens": 2939, "total_tokens": 5489, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1147}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 专家共识组 . 血脂康(胶囊)临床应 用中国专家共识(2017 修订版) [J]. 中华内科杂志, 2018, 57 (2):            97?100.             DOI:             10.3760/cma.           j. issn.0578?1426.2018.02.003.\n　Committee     of     Cardio?Cerebro?Vascular     Diseases     of Gerontological  Society  of  China,  the  Working   Group  of Chinese   Expert   Consensus   on  the   Use   of  Xuezhikang. Chinese expert consensus on the use of Xuezhikang (2017 revised edition)[J]. Chin J Intern Med, 2018, 57 (2):97?100. DOI: 10.3760/cma.j.issn.0578?1426.2018.02.003.\n[51]      Jia  W,  Li  Y,  Wan J,  et al.  Effects  of Xuezhitong  in  patients with   hypertriglyceridemia:   a   multicentre,   randomized, double?blind,    double    simulation,    positive     drug    and placebo  parallel  control  study[J].  Cardiovasc  Drugs  Ther, 2020,            34 (4):           525?534.            DOI:            10.1007/ s10557?020?06965?3.\n[52]      Dai  N,  Zhao  FF,  Fang  M, et al.  Gynostemma pentaphyllum for   dyslipidemia:   a   systematic   review   of   randomized controlled  trials[J].  Front  Pharmacol,  2022,   13: 917521. DOI: 10.3389/fphar.2022.917521.\n[53]      Xu RX, Wu NQ, Li S, et al. Effects of Hedan Tablet (荷丹片) on  lipid  profile,  proprotein  convertase  subtilisin/kexin type   9    and    high?density   lipoprotein    subfractions    in patients  with  hyperlipidemia:  a  primary  study[J].  Chin  J Integr    Med,     2016,    22 (9):    660?665.    DOI:     10.1007/ s11655?015?2140?3.\n[54]      Das  Pradhan  A,  Glynn  RJ,  Fruchart  JC,  et al.  Triglyceride lowering with  pemafibrate to  reduce  cardiovascular  risk [J].   N    Engl   J    Med,   2022,    387 (21):   1923?1934.    DOI: 10. 1056/NEJMoa2210645.\n[55]       Gordon   SM,  Amar   MJ,  Jeiran   K,   et al.   Effect   of  niacin monotherapy   on  high   density  lipoprotein   composition\n\n\nand function[J]. Lipids Health Dis, 2020,  19 (1): 190. DOI: 10.1186/s 12944?020?01350?3.\n[56]      Tadic  M,  Sala  C,  Grassi  G,  et al.  Omega?3  fatty  acids  and coronary artery disease: more questions than answers [J]. J     Clin     Med,     2021,     10 (11):    2495.     DOI:     10.3390/ jcm 10112495.\n[57]       Bhatt  DL,  Steg  PG,  Miller  M,  et al.   Cardiovascular  risk reduction  with  icosapent  ethyl  for  hypertriglyceridemia [J].  N  Engl  J   Med,  2019,  380 (1): 11?22.  DOI:  10.1056/ NEJMoa1812792.\n[58]      Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high?dose omega?3   fatty    acids    vs   corn   oil   on   major    adverse cardiovascular  events  in  patients  at  high  cardiovascular risk:  the  STRENGTH  Randomized  Clinical  Trial [J].  JAMA, 2020,         324 (22):         2268?2280.         DOI:          10.1001/ jama.2020.22258.\n[59]      Averna M, Banach M, Bruckert E, et al. Practical guidance for combination       lipid?modifying       therapy       in       high?and very?high?risk   patients:   a   statement   from   a   European Atherosclerosis Society Task Force [J]. Atherosclerosis,  2021, 325:99?109. DOI: 10.1016/j.atherosclerosis.2021.03.039.\n[60]      Goldberg AC, Leiter LA, Stroes E, et al. Effect of bempedoic acid vs  placebo  added to  maximally tolerated  statins  on low?density  lipoprotein  cholesterol  in  patients  at  high risk   for\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_97885d3d784ecc248d9ebeac8069badde1348fd7012f74f9e6b469fc6a600938_v2"}